Legend Biotech Corp Adjustments For Increase Decrease In Other Operating Payables
Legend Biotech Corp (LEGN) reported Adjustments For Increase Decrease In Other Operating Payables of $36.10 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables · last filed 2026-03-10
- Legend Biotech Corp adjustments for increase decrease in other operating payables for the quarter ending 2025-12-31 was $47.11M.
- Legend Biotech Corp adjustments for increase decrease in other operating payables for the quarter ending 2025-09-30 was $6.76M, a 552.75% increase year-over-year.
- Legend Biotech Corp adjustments for increase decrease in other operating payables for the quarter ending 2025-06-30 was $20.87M, a 46.13% decline year-over-year.
- Legend Biotech Corp adjustments for increase decrease in other operating payables for the quarter ending 2025-03-31 was -$38.63M, a 623.51% decline year-over-year.
| Period end | Adjustments For Increase Decrease In Other Operating Payables 3 month | Adjustments For Increase Decrease In Other Operating Payables 3 month as first filed | Adjustments For Increase Decrease In Other Operating Payables 6 month | Adjustments For Increase Decrease In Other Operating Payables 6 month as first filed | Adjustments For Increase Decrease In Other Operating Payables 9 month | Adjustments For Increase Decrease In Other Operating Payables 9 month as first filed | Adjustments For Increase Decrease In Other Operating Payables 12 month | Adjustments For Increase Decrease In Other Operating Payables 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $47.11M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $53.86M derived: sum of 2 quarters · filed 2026-03-10 | $74.73M derived: sum of 3 quarters · filed 2026-03-10 | $36.10M 20-F · filed 2026-03-10 | ||||
| 2025-09-30 | $6.76M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $27.63M derived: sum of 2 quarters · filed 2025-11-12 | -$11.01M 6-K · filed 2025-11-12 | -$14.27M derived: sum of 4 quarters · filed 2026-03-10 | ||||
| 2025-06-30 | $20.87M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$17.76M 6-K · filed 2025-08-11 | -$21.03M derived: sum of 3 quarters · filed 2026-03-10 | -$19.99M derived: sum of 4 quarters · filed 2026-03-10 | ||||
| 2025-03-31 | -$38.63M 6-K · filed 2025-05-13 | -$41.90M derived: sum of 2 quarters · filed 2026-03-10 | -$40.86M derived: sum of 3 quarters · filed 2026-03-10 | -$2.12M derived: sum of 4 quarters · filed 2026-03-10 | ||||
| 2024-12-31 | -$3.26M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$2.23M derived: sum of 2 quarters · filed 2026-03-10 | $36.52M derived: sum of 3 quarters · filed 2026-03-10 | $43.90M 20-F · filed 2026-03-10 | $45.69M 20-F · filed 2025-03-11 | |||
| 2024-09-30 | $1.03M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $39.78M derived: sum of 2 quarters · filed 2025-11-12 | $47.16M 6-K · filed 2025-11-12 | $49.79M 6-K · filed 2024-11-12 | $73.25M derived: sum of 4 quarters · filed 2026-03-10 | |||
| 2024-06-30 | $38.75M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $46.13M 6-K · filed 2025-08-11 | $47.69M 6-K · filed 2024-08-09 | $72.21M derived: sum of 3 quarters · filed 2026-03-10 | $63.69M derived: sum of 4 quarters · filed 2026-03-10 | |||
| 2024-03-31 | $7.38M 6-K · filed 2025-05-13 | $10.88M 6-K · filed 2024-05-13 | $33.46M derived: sum of 2 quarters · filed 2026-03-10 | $24.94M derived: sum of 3 quarters · filed 2026-03-10 | $43.86M derived: sum of 4 quarters · filed 2026-03-10 | |||
| 2023-12-31 | $26.08M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $17.56M derived: sum of 2 quarters · filed 2026-03-10 | $36.48M derived: sum of 3 quarters · filed 2026-03-10 | -$2.70M 20-F · filed 2026-03-10 | -$38.81M 20-F · filed 2024-03-19 | |||
| 2023-09-30 | -$8.52M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $10.40M derived: sum of 2 quarters · filed 2024-11-12 | -$28.78M 6-K · filed 2024-11-12 | -$27.04M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $18.92M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$20.26M 6-K · filed 2024-08-09 | -$18.52M derived: sum of 3 quarters · filed 2025-03-11 | $45.02M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | -$39.18M 6-K · filed 2024-05-13 | -$37.44M derived: sum of 2 quarters · filed 2025-03-11 | $26.10M derived: sum of 3 quarters · filed 2025-03-11 | |||||
| 2022-12-31 | $1.74M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $65.29M derived: sum of 2 quarters · filed 2025-03-11 | $119.29M 20-F · filed 2025-03-11 | $165.88M 20-F · filed 2023-03-30 | ||||
| 2022-09-30 | $63.54M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $117.54M 6-K · filed 2023-11-20 | ||||||
| 2022-06-30 | $54.00M 6-K · filed 2023-08-15 | |||||||
| 2021-12-31 | $140.75M 20-F · filed 2024-03-19 | $142.09M 20-F · filed 2022-03-31 | ||||||
| 2021-06-30 | $27.65M 6-K · filed 2021-08-23 | |||||||
| 2020-12-31 | $26.93M 20-F · filed 2023-03-30 | $20.23M 20-F · filed 2021-04-02 | ||||||
| 2020-06-30 | -$12.60M 6-K · filed 2021-08-23 | |||||||
| 2019-12-31 | $31.73M 20-F/A · filed 2023-02-17 | |||||||
| 2018-12-31 | $18.31M 20-F · filed 2021-04-02 |